Foghorn Therapeutics and Eli Lilly have decided not to advance the experimental cancer drug FHD-909 into the expansion portion of clinical development after reviewing data from a Phase 1 dose-escalation trial, the companies’ partner announced Thursday.
Watertown, Massachusetts-based Foghorn also said it will reduce its workforce by approximately 40% and redirect resources toward wholly owned research programs. The changes are expected to extend the company’s projected cash runway into the second half of 2029, according to its October 1 announcement.
What the companies decided
FHD-909, also known as LY4050784, is an oral drug designed to inhibit SMARCA2, a protein some tumors with SMARCA4 alterations may rely on. The first-in-human trial focused on patients with advanced solid tumors carrying those alterations, with non-small cell lung cancer a principal target population.
Foghorn said the dose-escalation study showed a favorable safety profile at drug exposures above its preclinical targets, but the clinical results did not demonstrate enough efficacy to justify moving into an expansion phase. The statement did not disclose a full patient-level data set.
The partners will also stop work on a separate selective SMARCA2 degrader program and do not expect further activities under the collaboration. Reuters independently reported the decision on October 1.
Why the Phase 1 result matters
Early dose-escalation trials are primarily designed to evaluate safety, tolerability and dosing, while also looking for preliminary signs of activity. Promising laboratory or animal results do not establish that a treatment will work in people.
That distinction is important in this case. In April, Foghorn reported preclinical tumor-regression results for FHD-909 in combination with an anti-PD-1 antibody. Its October update says the biological strategy did not translate into the level of clinical efficacy needed to continue. The decision therefore concerns the development program—not a regulatory withdrawal of an approved medicine. FHD-909 has not been approved for patient use.
Foghorn’s workforce and pipeline reset
Foghorn said the approximately 40% workforce reduction and other operating changes will concentrate spending on four areas:
- a selective EP300 degrader program;
- a novel oral immunology and inflammation program;
- a selective CBP degrader program; and
- the company’s induced-proximity research platform.
The projected runway into the second half of 2029 is a company estimate, not a guarantee. It depends on spending, development timelines and other assumptions that can change.
The reset is a material change from Foghorn’s August update, when the company said FHD-909 dose escalation was progressing and reported $167.6 million in cash, cash equivalents and marketable securities as of June 30. At that time, it projected funding into the first half of 2028. The new, longer forecast reflects the narrower pipeline and planned cost reductions rather than new evidence that the remaining drug candidates will succeed.
What patients and investors should know
For trial participants, the company’s announcement does not provide individualized medical guidance. Patients enrolled in or screened for the study should get information from their trial site or treating clinician. The trial’s public registry and site contacts are the appropriate places for enrollment-status updates.
For readers following the biotechnology sector, the episode illustrates the gap between encouraging preclinical research and clinical evidence. AskNovus recently reported that UniQure’s four-year Huntington’s gene-therapy analysis missed a statistical threshold, while another recent deal saw AstraZeneca agree to invest in Summit Therapeutics. Each program has different biology, trial design and evidence; none should be treated as a read-through for another.
Foghorn said it will focus on moving the remaining proprietary programs toward the clinic. Future regulatory filings and trial registrations will be the key sources for specific timelines, study designs and financial effects.
Sources checked October 1, 2026: Foghorn Therapeutics announcement; Reuters; Foghorn’s August 6 financial and pipeline update.
Featured image: National Cancer Institute/Unsplash.